Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:11 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Hemoglobin Optimization to Prevent Transfusion and Adverse Events in Perioperative Patients With Iron Restricted Anemia
NCT03528564 · Unity Health Toronto · PHASE2 · terminated · last registry update 2021-06-18 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The primary reasoning is that we were unable to demonstrate feasibility, prior to and because of the impact of COVID on our research programs.” | – | Registry record, Unity Health Toronto |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against EPOR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-05-27Phase 3 first posted: Imperial College London, Erythropoietin (NCT05395195)
- 2022-04-14Results posted on the registry: GlaxoSmithKline, Daprodustat + Darbepoetin alfa (NCT02876835)
- 2022-03-29Phase 3 first posted: Kyntra Bio, SEPO® + Roxadustat (NCT05301517)
- 2022-03-21Results posted on the registry: American Regent, Inc., Ferric carboxymaltose (NCT04269707)
- 2022-03-07Results posted on the registry: Hoffmann-La Roche, Mircera (NCT03552393)
- 2022-03-04Also stopped (terminated): University Hospital, Brest, Reticera (NCT02832323)
- 2022-02-10Results posted on the registry: Kyntra Bio, Roxadustat (NCT01244763)
- 2022-01-27Phase 3 first posted: Shenyang Sunshine Pharmaceutical Co., LTD., Human Erythropoiesis Injection (CHO cell) + Recombinant Erythropoiesis Stimulating Protein Injection(CHO cell) (NCT05211167)
- 2022-01-11Results posted on the registry: Kyntra Bio, Roxadustat + Epoetin Alfa (NCT01147666)
- 2021-12-28Also stopped (terminated): Saint-Joseph University, Erythropoietin (NCT03401710)
- 2021-12-03Results posted on the registry: GlaxoSmithKline, Daprodustat + rhEPO (NCT02879305)
- 2021-12-02Results posted on the registry: University of California, San Diego, Epoetin Alfa and Iron + Iron (NCT02564796)
- 2021-12-02Also stopped (terminated): University of California, San Diego, Epoetin Alfa and Iron + Iron (NCT02564796)
- 2021-11-19Results posted on the registry: Kyntra Bio, Roxadustat + Placebo (NCT00761657)
- 2021-11-03Results posted on the registry: GlaxoSmithKline, Daprodustat (GSK1278863) + Placebo (NCT03409107)
- 2021-10-29Results posted on the registry: Kyntra Bio, Epoetin Alfa + Roxadustat (NCT02273726)
- 2021-10-20Results posted on the registry: GlaxoSmithKline, Daprodustat + Darbepoetin alfa (NCT03029208)
- 2021-10-15Phase 3 first posted: University Hospital, Angers, Erythropoietin + Placebo (NCT05080049)
- 2021-10-01Results posted on the registry: Kyntra Bio, Roxadustat + Epoetin Alfa (NCT02052310)
- 2021-10-01Results posted on the registry: Kyntra Bio, Roxadustat + Oral Iron (NCT01414075)
- 2021-10-01Results posted on the registry: Kyntra Bio, Roxadustat (NCT01630889)
- 2021-09-29Also stopped (withdrawn): Seoul National University Hospital, Erythropoietin (NCT03004209)
- 2021-08-06Also stopped (withdrawn): University of Louisville, Procrit + Placebo (NCT00624312)
- 2021-07-21Results posted on the registry: GlaxoSmithKline, Daprodustat + Darbepoetin alfa (NCT03446612)
- 2021-07-13Also stopped (terminated): Shire, Dynepo (NCT00514813)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision